Latest & greatest articles for nivolumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nivolumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nivolumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nivolumab

121. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. Full Text available with Trip Pro

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity.In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had progressed during or after platinum-based doublet chemotherapy to receive nivolumab at a dose of 3 mg per kilogram (...) of body weight every 2 weeks or docetaxel at a dose of 75 mg per square meter of body-surface area every 3 weeks. The primary end point was overall survival.Overall survival was longer with nivolumab than with docetaxel. The median overall survival was 12.2 months (95% confidence interval [CI], 9.7 to 15.0) among 292 patients in the nivolumab group and 9.4 months (95% CI, 8.1 to 10.7) among 290 patients in the docetaxel group (hazard ratio for death, 0.73; 96% CI, 0.59 to 0.89; P=0.002). At 1 year

2015 NEJM Controlled trial quality: predicted high

122. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. Full Text available with Trip Pro

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment.A total of 821 patients with advanced clear-cell renal-cell carcinoma (...) for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety.The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 to not estimable) with nivolumab

2015 NEJM Controlled trial quality: predicted high

123. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. Full Text available with Trip Pro

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. 26398076 2015 09 24 2018 12 02 1533-4406 373 13 2015 09 24 The New England journal of medicine N. Engl. J. Med. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. 1270-1 10.1056/NEJMc1509660 Larkin James J Hodi F Stephen FS Wolchok Jedd D JD eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antibodies, Monoclonal AIM IM N Engl J Med. 2015 Jul 2;373(1):23-34 26027431 N Engl J Med. 2015

2015 NEJM

124. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. Full Text available with Trip Pro

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. 26398077 2015 09 24 2018 12 02 1533-4406 373 13 2015 09 24 The New England journal of medicine N. Engl. J. Med. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. 1270 10.1056/NEJMc1509660 Valsecchi Matias E ME eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antibodies, Monoclonal AIM IM N Engl J Med. 2015 Jul 2;373(1):23-34 26027431 N Engl J Med. 2015 Sep 24;373(13):1270-1 26398076

2015 NEJM

125. Nivolumab (Opdivo) Metastatic Melanoma - Details

Nivolumab (Opdivo) Metastatic Melanoma - Details Opdivo for Metastatic Melanoma - Details | CADTH.ca Find the information you need Opdivo for Metastatic Melanoma - Details Opdivo for Metastatic Melanoma - Details Project Number pCODR 10063 Brand Name Opdivo Generic Name Nivolumab Strength 40mg/4mL and 100mg/10mL vials Tumour Type Skin and Melanoma Indication Metastatic Melanoma Funding Request For the treatment of both first-line and previously-treated advanced adult melanoma patients (...) has been granted for nivolumab (Opdivo). In accordance with the pCODR Procedures, the pCODR Provincial Advisory Group (PAG) requested additional information on nivolumab (Opdivo) which extends beyond the submitted scope of the review. Revision of review scope may be considered by pCODR in very limited instances, based on jurisdictional input, feasibility to conduct the revised review and clinical importance. All three criteria for scope modification were met in this case. The timeline

2015 CADTH - Pan Canadian Oncology Drug Review

126. Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma

Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA). Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology No. 50. 2015 Project page URL Final publication URL PubMedID Indexing Status Subject indexing assigned by NLM MeSH Antibodies, Monoclonal /therapeutic use; Antineoplastic

2015 Health Technology Assessment (HTA) Database.

127. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. Full Text available with Trip Pro

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab plus ipilimumab was compared with ipilimumab alone in patients with metastatic melanoma.We assigned, in a 1:1:1 ratio, 945 (...) previously untreated patients with unresectable stage III or IV melanoma to nivolumab alone, nivolumab plus ipilimumab, or ipilimumab alone. Progression-free survival and overall survival were coprimary end points. Results regarding progression-free survival are presented here.The median progression-free survival was 11.5 months (95% confidence interval [CI], 8.9 to 16.7) with nivolumab plus ipilimumab, as compared with 2.9 months (95% CI, 2.8 to 3.4) with ipilimumab (hazard ratio for death or disease

2015 NEJM Controlled trial quality: predicted high

128. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. Full Text available with Trip Pro

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, as compared with docetaxel in this patient population.We (...) randomly assigned 272 patients to receive nivolumab, at a dose of 3 mg per kilogram of body weight every 2 weeks, or docetaxel, at a dose of 75 mg per square meter of body-surface area every 3 weeks. The primary end point was overall survival.The median overall survival was 9.2 months (95% confidence interval [CI], 7.3 to 13.3) with nivolumab versus 6.0 months (95% CI, 5.1 to 7.3) with docetaxel. The risk of death was 41% lower with nivolumab than with docetaxel (hazard ratio, 0.59; 95% CI, 0.44

2015 NEJM Controlled trial quality: predicted high

129. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. Full Text available with Trip Pro

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma.In this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment, we randomly assigned patients in a 2:1 ratio to receive ipilimumab (3 mg per (...) kilogram of body weight) combined with either nivolumab (1 mg per kilogram) or placebo once every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) or placebo every 2 weeks until the occurrence of disease progression or unacceptable toxic effects. The primary end point was the rate of investigator-assessed, confirmed objective response among patients with BRAF V600 wild-type tumors.Among patients with BRAF wild-type tumors, the rate of confirmed objective response was 61% (44 of 72

2015 NEJM Controlled trial quality: predicted high

130. Nivolumab (Opdivo) for first-line treatment of advanced melanoma

Nivolumab (Opdivo) for first-line treatment of advanced melanoma Nivolumab (Opdivo) for first-line treatment of advanced melanoma Nivolumab (Opdivo) for first-line treatment of advanced melanoma HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Nivolumab (Opdivo) for first-line treatment of advanced melanoma. Lansdale: HAYES, Inc

2015 Health Technology Assessment (HTA) Database.

131. Nivolumab (Opdivo) for recurrent or metastatic squamous cell carcinoma of the head and neck - second line

Nivolumab (Opdivo) for recurrent or metastatic squamous cell carcinoma of the head and neck - second line Nivolumab (Opdivo) for recurrent or metastatic squamous cell carcinoma of the head and neck – second line Nivolumab (Opdivo) for recurrent or metastatic squamous cell carcinoma of the head and neck – second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation NIHR HSRIC. Nivolumab (Opdivo) for recurrent or metastatic squamous cell carcinoma of the head and neck – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Head and neck cancer is a rare type of cancer. There are over 30 areas in the head and neck where the cancer can develop, for example, the mouth, nose, sinuses and throat. Tobacco smoking and alcohol are known to increase the risk of developing head

2015 Health Technology Assessment (HTA) Database.

132. Nivolumab (Opdivo) for Hodgkin lymphoma in brentuximab treated patients - second line

Nivolumab (Opdivo) for Hodgkin lymphoma in brentuximab treated patients - second line Nivolumab (Opdivo) for Hodgkin lymphoma in brentuximab treated patients – second line Nivolumab (Opdivo) for Hodgkin lymphoma in brentuximab treated patients – second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Nivolumab (Opdivo) for Hodgkin (...) lymphoma in brentuximab treated patients – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Hodgkin lymphoma is a cancer of the lymphatic system – part of the body's immune system. In Hodgkin lymphoma, blood cells called lymphocytes become abnormal, increase in number and collect in the lymph nodes (glands) and other organs. Nivolumab is a new antibody drug for the treatment of Hodgkin lymphoma, and is delivered straight

2015 Health Technology Assessment (HTA) Database.

133. Nivolumab (Opdivo) for Hodgkin lymphoma in brentuximab na?ve patients - second line

Nivolumab (Opdivo) for Hodgkin lymphoma in brentuximab na?ve patients - second line Nivolumab (Opdivo) for Hodgkin lymphoma in brentuximab naïve patients – second line Nivolumab (Opdivo) for Hodgkin lymphoma in brentuximab naïve patients – second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Nivolumab (Opdivo) for Hodgkin lymphoma (...) in brentuximab naïve patients – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Hodgkin lymphoma is a cancer of the lymphatic system – part of the body's immune system. In Hodgkin lymphoma, blood cells called lymphocytes become abnormal, increase in number and collect in the lymph nodes (glands) and other organs. Nivolumab is a new antibody drug for the treatment of Hodgkin lymphoma, and is delivered straight into the bloodstream

2015 Health Technology Assessment (HTA) Database.

134. Nivolumab (Opdivo) for diffuse large B cell lymphoma -second line

Nivolumab (Opdivo) for diffuse large B cell lymphoma -second line Nivolumab (Opdivo) for diffuse large B cell lymphoma –second line Nivolumab (Opdivo) for diffuse large B cell lymphoma –second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Nivolumab (Opdivo) for diffuse large B cell lymphoma –second line. Birmingham: NIHR Horizon (...) Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Lymphoma is a cancer of the lymphatic system, which is part of the immune system. It contains cells called lymphocytes that fight infections. Diffuse large B cell lymphoma is the most common type of non-Hodgkin's lymphoma. It can occur at any age but is more common in those over 65 years of age. Nivolumab is a new antibody drug for the treatment of diffuse large B cell lymphoma and is delivered straight

2015 Health Technology Assessment (HTA) Database.

135. Nivolumab (Nivolumab BMS©) for the second-line therapy of metastatic squamous non-small cell lung cancer

Nivolumab (Nivolumab BMS©) for the second-line therapy of metastatic squamous non-small cell lung cancer Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA). Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). Decision Support Document: Horizon Scanning in Oncology No. 53. 2015 Authors' conclusions Nivolumab is the first immunotherapy medicine licensed in the European

2015 Health Technology Assessment (HTA) Database.

136. Nivolumab for recurrent glioblastoma - second line

Nivolumab for recurrent glioblastoma - second line Nivolumab for recurrent glioblastoma – second line Nivolumab for recurrent glioblastoma – second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Nivolumab for recurrent glioblastoma – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review (...) . 2015 Authors' objectives Glioblastoma is a type of brain cancer that develops from cells that support nerve tissue. Glioblastoma is the most common type of brain cancer. After surgery or chemotherapy, this cancer often returns and most patients with glioblastoma do not survive for very long after their diagnosis. Nivolumab is a new antibody drug for the treatment of glioblastoma and is delivered straight into the bloodstream via a drip. It may stimulate the immune system to attack cancer cells

2015 Health Technology Assessment (HTA) Database.

137. Nivolumab BMS

Nivolumab BMS EMA/351429/2015 EMEA/H/C/003840 EPAR summary for the public Nivolumab BMS nivolumab This is a summary of the European public assessment report (EPAR) for Nivolumab BMS. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Nivolumab BMS. For practical information about using Nivolumab BMS, patients should read the package leaflet or contact their doctor (...) or pharmacist. What is Nivolumab BMS and what is it used for? Nivolumab BMS is a cancer medicine used to treat adults with a type of lung cancer called squamous non-small cell lung cancer (NSCLC). It is used in patients whose disease has spread locally or to other parts of the body and who have previously been treated with other cancer medicines (chemotherapy). The medicine contains the active substance nivolumab. How is Nivolumab BMS used? Nivolumab BMS can only be obtained with a prescription

2015 European Medicines Agency - EPARs

138. Opdivo - nivolumab

Opdivo - nivolumab 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 23 April 2015 EMA/CHMP/76688/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report OPDIVO International non-proprietary name: nivolumab Procedure No. EMEA/H/C/003985/0000 Note Assessment report as adopted by the CHMP with all information (...) of a commercially confidential nature deleted. Assessment report EMA/CHMP/76688/2015 Page 2/130 Administrative information Name of the medicinal product: OPDIVO Applicant: Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH UNITED KINGDOM Active substance: nivolumab International Nonproprietary Name/Common Name: nivolumab Pharmaco-therapeutic group (ATC Code): L01XC17 Therapeutic indication(s): OPDIVO as monotherapy is indicated for the treatment of advanced (unresectable

2015 European Medicines Agency - EPARs

139. Nivolumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V (dossier assessment)

Nivolumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Nivolumab (neues Anwendungsgebiet) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 12 November 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A15-32 Nivolumab (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A15-32 Version 1.0 Nivolumab (new TI) – Benefit assessment acc. to §35a Social Code Book V 12 Nov 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (new therapeutic indication) – Benefit assessment according to §35a SGB V Commissioning

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

140. Nivolumab: benefit assessment according to §35a Social Code Book V (dossier assessment)

Nivolumab: benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Nivolumab – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 October 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A15-27 Nivolumab – Benefit assessment (...) according to §35a Social Code Book V 1 Extract of dossier assessment A15-27 Version 1.0 Nivolumab – Benefit assessment acc. to §35a Social Code Book V 13 October 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 15 July 2015 Internal Commission No.: A15-27

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)